The Use of AI in Medicine: Health Data, Privacy Risks and More
Abstract
In the era of advancements in artificial intelligence (AI) and machine learning, the healthcare industry has become one of the major areas where such technologies are being actively adopted and utilized. The global health care sector generated more than 2.3 zettabytes of data worldwide in 2020. Analysts estimate that the global market for artificial intelligence (AI) in medicine will grow to $13 billion by 2025, with a significant increase in newly established companies. Artificial intelligence in medicine is used to predict, detect and diagnose various diseases and pathologies. The sources of data can be various results of medical research (EEG, X-ray images, laboratory tests, e.g. tissues, etc.). At the same time, there are understandable concerns that AI will undermine the patient-provider relationship, contribute to the deskilling of providers, undermine transparency, misdiagnose or inappropriately treat because of errors within AI decision-making that are hard to detect, exacerbate existing racial or societal biases, or introduce algorithmic bias that will be hard to detect. Traditional research methods, general and special ones, with an emphasis on the comparative legal method, were chosen. For the AI to work it needs to be trained, and it’s learning from all sorts of information given to it. The main part of the information on which AI is trained is health data, which is sensitive personal data. The fact that personal data is qualified as sensitive personal data indicates the significance of the information contained, the high risks in case it’s leaking, and hence the need for stricter control and regulation. The article offers a detailed exploration of the legal implications of AI in medicine, highlighting existing challenges, the current state of regulation, and proposes future perspectives and recommendations for legislation adapted to the era of medical AI. Given the above, the study is divided into three parts: international framework, that will focus primarily on applicable WHO documents; risks and possible ways to minimize them, where the authors have tried to consider various issues related to the use of AI in medicine and find options to address them; and relevant case-study.
References
Alekseeva M.G., Zubov A.I., Novikov M. Yu. (2022) Artificial Intelligence in Medicine. Mezhdunarodnyi nauchno-issledovatel’skii zhurnal=International Research Journal, no. 7, pp. 10–13 (in Russ.)
Boniolo F. et al. (2021) Artificial Intelligence in Early Drug Discovery Enabling Precision Medicine. Expert Opinion on Drug Discovery, vol. 16, no. 9, pp. 991–1007. DOI: https://doi.org/10.1080/17460441.2021.1918096 DOI: https://doi.org/10.1080/17460441.2021.1918096
Chen C.W., Walter P., Wei J.C. (2024) Using ChatGPT-Like Solutions to Bridge the Communication Gap Between Patients With Rheumatoid Arthritis and Health Care Professionals. Journal of Medical International Research Medical Education. Available at: https://doi.org/10.1186/s13643-022-01939-y (accessed: 16.05.2024) DOI: https://doi.org/10.2196/48989
Chung J., Zink A. (2018) Asia Pacific Journal of Health Law & Ethics, vol.11, no. 2, pp. 51–80.
Da Silva M. et al. (2022) Legal Concerns in Health-Related Artificial Intelligence: a Scoping Review Protocol. Systematic Reviews, no. 11. Available at: https://doi.org/10.1186/s13643-022-01939-y (accessed: 18.07.2023) DOI: https://doi.org/10.1186/s13643-022-01939-y
Hodge S.D. (2022) The Medical and Legal Implications of Artificial Intelligence in Health Care — An Area of Unsettled Law. Richmond Journal of Law & Technology, vol. XXVIII, issue 3, pp. 405–468.
Imameeva R.D. (2021) The Risks of Creation and Functioning of Artificial Intelligence in Medicine. Vestnik Moskovskogo universiteta imeni S. Yu. Vitte. Seriya 2: Yuridicheskie nauki=Bulletin of Moscow Witte University. Series 2: Legal Science, no. 1, pp. 33–40. DOI: 10.21777/2587-9472-2021-1-33-40 (in Russ.) DOI: https://doi.org/10.21777/2587-9472-2021-1-33-40
McCaffrey P. (2022) Artificial Intelligence for Vaccine Design. Methods in Molecular Biology, vol. 2412, pp. 3–13. DOI: 10.1007/978-1-0716-1892-9_1 DOI: https://doi.org/10.1007/978-1-0716-1892-9_1
McNair D., Price W.N. (2019) Health Care AI: Law, Regulation, and Policy. In: Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril. M. Matheny et al. (eds.) Washington: National Association of Medicine, pp. 181–213.
Naik N. et al. (2022) Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility? Frontiers in Surgery, vol. 9. DOI: https://doi.org/10.3389/fsurg.2022.862322 DOI: https://doi.org/10.3389/fsurg.2022.862322
Price W.N. (2017) Artificial Intelligence in Health Care: Applications and Legal Implications. The SciTech Lawyer, vol. 14, no. 1.
Price W.N., Sachs R., Eisenberg R.S. (2021) New Innovation Models in Medical AI. Law & Economics Working Papers. 47 p. DOI: https://doi.org/10.2139/ssrn.3783879
Spector-Bagdady K., Armoundas A.A. et al. (2023) Principles for Health Information Collection, Sharing, and Use: A Policy Statement From the American Heart Association. Circulation, vol. 148, pp. 1061–1069. DOI: 10.1161/CIR.0000000000001173 DOI: https://doi.org/10.1161/CIR.0000000000001173
Stöger K., Schneeberger D., Kiesebergc P., Holzinger A. (2021) Legal Aspects of Data Cleansing in Medical AI. Computer Law & Security Review, vol. 42. DOI: https://doi.org/10.1016/j.clsr.2021.105587 DOI: https://doi.org/10.1016/j.clsr.2021.105587
Thomas S. at al. (2022) Artificial Intelligence in Vaccine and Drug Design. Methods in Molecular Biology, vol. 2410, pp. 131–146. DOI: 10.1007/978-1-0716-1884-4_6 DOI: https://doi.org/10.1007/978-1-0716-1884-4_6
Authors who publish with this journal agree to the Licensing, Copyright, Open Access and Repository Policy.